share_log

BioVie | 10-Q: Q1 2025 Earnings Report

BioVie | 10-Q: Q1 2025 Earnings Report

BioVie | 10-Q:2025財年一季報
美股SEC公告 ·  11/14 05:52

牛牛AI助理已提取核心訊息

BioVie Inc., a clinical-stage company focusing on drug therapies for chronic debilitating conditions, reported its financial performance for the quarter ended September 30, 2024. The company experienced a net loss of approximately $4.2 million, a decrease from the net loss of $10.7 million in the same period the previous year. This reduction was primarily due to a decrease in research and development expenses, which dropped by approximately $6.9 million as a result of completed clinical trials in the prior fiscal year. Selling, general, and administrative expenses saw a slight increase of approximately $132,000, mainly due to higher legal fee expenses. Other expenses netted to approximately $30,000, compared to other income of $165,000 in the previous year. The company's cash and cash equivalents stood at approximately $20.0 million...Show More
BioVie Inc., a clinical-stage company focusing on drug therapies for chronic debilitating conditions, reported its financial performance for the quarter ended September 30, 2024. The company experienced a net loss of approximately $4.2 million, a decrease from the net loss of $10.7 million in the same period the previous year. This reduction was primarily due to a decrease in research and development expenses, which dropped by approximately $6.9 million as a result of completed clinical trials in the prior fiscal year. Selling, general, and administrative expenses saw a slight increase of approximately $132,000, mainly due to higher legal fee expenses. Other expenses netted to approximately $30,000, compared to other income of $165,000 in the previous year. The company's cash and cash equivalents stood at approximately $20.0 million, with working capital of approximately $13.3 million and stockholders' equity of approximately $14.1 million. BioVie's future operations hinge on the success of ongoing development and commercialization efforts, as well as its ability to secure additional financing. The company relies on third parties to conduct its clinical trials, which poses risks related to compliance with regulatory standards and potential delays. BioVie also faces risks associated with the financial services industry, as it holds cash deposits exceeding federally insured levels. The company's common stock may experience future dilution due to potential equity offerings or the issuance of shares subject to options, warrants, stock awards, or other arrangements.
BioVie Inc.是一家專注於慢性致殘疾病藥物治療的臨床階段公司,報告了截至2024年9月30日的季度財務業績。公司經歷了約420萬美元的淨虧損,較去年同期的1070萬美元淨虧損有所減少。這一減少主要是由於研究和開發支出的降低,研究和開發支出約減少了690萬美元,原因是前一個財政年度完成了臨床試驗。銷售、一般和管理費用略微增加了約132,000美元,主要是由於法律費用的增加。其他費用淨額約爲30,000美元,而去年同期的其他收入爲165,000美元。公司的現金及現金等價物約爲2000萬美元,營運資金約爲1330萬美元,股東權益約爲1410萬美元。BioVie未來的運營依賴於正在進行的開發和...展開全部
BioVie Inc.是一家專注於慢性致殘疾病藥物治療的臨床階段公司,報告了截至2024年9月30日的季度財務業績。公司經歷了約420萬美元的淨虧損,較去年同期的1070萬美元淨虧損有所減少。這一減少主要是由於研究和開發支出的降低,研究和開發支出約減少了690萬美元,原因是前一個財政年度完成了臨床試驗。銷售、一般和管理費用略微增加了約132,000美元,主要是由於法律費用的增加。其他費用淨額約爲30,000美元,而去年同期的其他收入爲165,000美元。公司的現金及現金等價物約爲2000萬美元,營運資金約爲1330萬美元,股東權益約爲1410萬美元。BioVie未來的運營依賴於正在進行的開發和商業化努力的成功,以及其獲得額外融資的能力。公司依賴第三方進行臨床試驗,這帶來了與合規性相關的風險以及潛在的延誤。BioVie還面臨與金融服務行業相關的風險,因爲它持有的現金存款超過了聯邦保險水平。由於潛在的股權發行或股票期權、warrants、股票獎勵或其他安排的股份發行,公司普通股未來可能面臨稀釋。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。